Australia Biotech Invest returning to Melbourne

Following a successful debut in 2013, the Australia Biotech Invest conference will return to Melbourne from 3-4 December.

Organised by AusBiotech and Beacon Events, the event brings together life science investors with biotech innovators from Australia and worldwide. Its high-quality program will update attendees on the key trends in biotech investment, partnering and capital raising in Australia and globally.

The life science investment showcase will feature over 40 biotech company presentations, including 5-10 international companies, as well as expert panellists and keynote speakers from across the world. Clinical Genomics CEO Dr Larry LaPointe will be one such presenter, showcasing the company’s recent progress and pipeline at the conference.

Dr LaPointe’s presentation comes on the heels of a recent licensing deal with CSIRO related to Clinical Genomics’ emerging DNA test for bowel cancer and a distribution deal in China for its faecal immunochemical test (FIT). He said, “As a company with positive cash flow and an exciting pipeline in a growing sector, we look forward to telling our story and to identifying the best partners.”

Attendance at the event provides delegates, investors and companies with exclusive access to the BioInvest online partnering system - an opportunity to prearrange one-on-one meetings to take place during the event. This system has been responsible for many fruitful discussions, which have led to deals taking place between investors and biotech companies.

For more information on the event and to register, visit http://ausbiotechinvest.com/.